Cargando…

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

BACKGROUND: Alzheimer's disease (AD) is characterized by early and region-specific declines in cerebral glucose metabolism. Ketone bodies are produced by the body during glucose deprivation and are metabolized by the brain. An oral ketogenic compound, AC-1202, was tested in subjects with probab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henderson, Samuel T, Vogel, Janet L, Barr, Linda J, Garvin, Fiona, Jones, Julie J, Costantini, Lauren C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731764/ https://www.ncbi.nlm.nih.gov/pubmed/19664276 http://dx.doi.org/10.1186/1743-7075-6-31

Ejemplares similares

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
por: Lawlor, Brian, et al.
Publicado: (2014)

Hypometabolism as a therapeutic target in Alzheimer's disease
por: Costantini, Lauren C, et al.
Publicado: (2008)

Physics in Pisa 1202-1938: a survey
por: Barcaro, Umberto, et al.
Publicado: (1987)

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
por: Xiao, Shifu, et al.
Publicado: (2021)

Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study
por: Kasugai, Kunio, et al.
Publicado: (2019)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19
por: Nicastri, Emanuele, et al.
Publicado: (2022)

Ketogenic Effects of Multiple Doses of a Medium Chain Triglycerides Enriched Ketogenic Formula in Healthy Men under the Ketogenic Diet: A Randomized, Double-Blinded, Placebo-Controlled Study
por: Nakamura, Kentaro, et al.
Publicado: (2022)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

MicroRNA-1202 plays a vital role in osteoarthritis via KCNQ1OT1 has-miR-1202-ETS1 regulatory pathway
por: Liu, Changzeng, et al.
Publicado: (2020)

P1202: NOVEL METHODS FOR THE IDENTIFICATION OF A RARE DISEASE, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)
por: Broome, Catherine M, et al.
Publicado: (2023)

Krill oil improved osteoarthritic knee pain in adults with mild to moderate knee osteoarthritis: a 6-month multicenter, randomized, double-blind, placebo-controlled trial
por: Stonehouse, Welma, et al.
Publicado: (2022)

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
por: Rossignol, Jean-François, et al.
Publicado: (2022)

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study
por: Henderson, Samuel T, et al.
Publicado: (2011)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
por: Fujino, Takehiko, et al.
Publicado: (2017)

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
por: Wade, Alan G, et al.
Publicado: (2014)

Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: A randomized, double-blind, and placebo-controlled study
por: Akhgarjand, Camellia, et al.
Publicado: (2022)

1202. It’s a Confidence Scheme—Transmission-based Precautions in the Ambulatory Setting
por: McQuaide, Colleen, et al.
Publicado: (2019)

1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
por: Serio, Alisa W, et al.
Publicado: (2020)

Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients
por: Edahiro, Yoko, et al.
Publicado: (2022)

Efficacy and Safety of Jueyin Granules for Patients with Mild-to-Moderate Psoriasis Vulgaris: Protocol for a Multicenter Randomized Placebo-Controlled Trial
por: Li, Su, et al.
Publicado: (2020)

Sodium Hypochlorite 0.005% Versus Placebo in the Treatment of Mild to Moderate Acne: A Double-Blind Randomized Controlled Trial
por: Dorostkar, Azadeh, et al.
Publicado: (2021)

The effect of Melissa officinalis syrup on patients with mild to moderate psoriasis: a randomized, double-blind placebo-controlled clinical trial
por: Yargholi, Alireza, et al.
Publicado: (2021)

Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
por: Manomaipiboon, Anan, et al.
Publicado: (2022)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

1202. Chagas Disease Awareness in a Hispanic Community of the Greater New Orleans Area
por: Hincapie, Marcela, et al.
Publicado: (2021)

Conducting double-blind placebo-controlled clinical trials of transcranial alternating current stimulation (tACS)
por: Frohlich, Flavio, et al.
Publicado: (2021)

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study
por: Marashian, Seyed Mehran, et al.
Publicado: (2022)

Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
por: Wada, Tatsuhiko, et al.
Publicado: (2023)

Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial
por: Zheng, Jin-ping, et al.
Publicado: (2023)

Speed of Processing (SoP) Training Plus α-tACS in People With Mild Cognitive Impairment: A Double Blind, Parallel, Placebo Controlled Trial Study Protocol
por: Leite, Jorge, et al.
Publicado: (2022)

OA12.02. CAM utilization among underserved patients in a safety-net hospital
por: Gardiner, P
Publicado: (2012)

MA12.02 Factors Associated with Severe COVID-19 Infections in Lung Cancer Patients
por: Ganti, A.K., et al.
Publicado: (2021)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Ketogenic Diet in Alzheimer’s Disease
por: Rusek, Marta, et al.
Publicado: (2019)

A double-blind, placebo-controlled clinical trial to assess the effects of a combined nutraceutical on endothelial function in patients with mild-to-moderate hypercholesterolaemia
por: Pecchioli, Valerio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r1do8cks7kuhi74897a3e9ibmf